{"entity":{"id":"experimental-versus-clinical-exposure","kind":"term","name":"Experimental and clinical drug exposure","aka":["clinically relevant experimental concentrations","in vitro to clinical exposure bridge"],"tldr":"A drug concentration that affects cells in a dish may differ from what can safely reach a tumor. Exposure includes the amount of drug, how long it remains available and the setting in which it is measured.","summary":"A primary compilation of oncology drug pharmacokinetics showed why nonclinical studies need concentrations relevant to measured human exposures. A high-concentration experiment can help investigate a mechanism without establishing that the effect is achievable clinically. Plasma concentration, free drug, exposure duration and tumor delivery are separate quantities; a reported peak concentration is not a universal concentration to use in every assay. The comparison must fit the drug, measured species and experimental conditions.","asOf":"2026-11-08","links":[{"label":"Clinically relevant concentrations for nonclinical studies (2017)","url":"https://doi.org/10.1158/1078-0432.CCR-16-3083"}],"tags":[],"related":["pharmacokinetics","dose","drug-target-engagement","drug-response-sensitivity"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Methods and models"},"route":"/terms/experimental-versus-clinical-exposure/","neighbours":{"term":[{"id":"binding-site-barrier","kind":"term","name":"Binding-site barrier in tumor delivery","route":"/terms/binding-site-barrier/"},{"id":"model-context-of-use","kind":"term","name":"Context of use for a tumor model","route":"/terms/model-context-of-use/"},{"id":"dose","kind":"term","name":"Dose","route":"/terms/dose/"},{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","route":"/terms/drug-response-sensitivity/"},{"id":"drug-target-engagement","kind":"term","name":"Drug target engagement","route":"/terms/drug-target-engagement/"},{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","route":"/terms/measurement-to-benefit-evidence/"},{"id":"growth-rate-inhibition","kind":"term","name":"Growth-rate correction in drug-response assays","route":"/terms/growth-rate-inhibition/"},{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/"}]}}